CompletedNot Applicable

Comparative Effects of CGF and PRP in Impacted Third Molar Surgery

Turkey (Türkiye)42 participantsStarted 2024-05-02

Plain-language summary

This study evaluates the effects of two different blood products obtained from the patient's own blood (Concentrated Growth Factor \[CGF\] and Platelet-Rich Plasma \[PRP\]) on healing after wisdom tooth extraction. The aim is to determine whether applying these materials to the extraction area reduces postoperative pain, facial swelling, and the risk of dry socket compared to standard healing.

Who can participate

Age range

18 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged between 18 and 50 years. * Systemically healthy individuals classified as American Society of Anesthesiologists (ASA) Class I or Class II. * Presence of impacted mandibular third molars (teeth 38 and 48 according to Fédération Dentaire Internationale (FDI) notation). * Mesioangular impaction with bone retention according to Winter's classification. * Class II relationship to the ramus according to the Pell and Gregory classification. * Level B or Level C depth of impaction according to the Pell and Gregory classification. Exclusion Criteria: * Patients younger than 18 years. * Habitual smoking or alcohol consumption. * Presence of coagulation (bleeding) disorders. * Systemic diseases affecting wound healing or use of medications that compromise healing. * Pregnancy or lactation. * Presence of active pericoronitis associated with the tooth. * Presence of pathological lesions (cysts or tumors) associated with the impacted tooth. * Uncontrolled periodontal disease in the oral cavity. * Known allergy to any medications used in the study protocol. * Inability to comply with follow-up visits.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Postoperative Pain

Timeframe: Postoperative days 1, 3, and 7.

Trial details

NCT IDNCT07320170

SponsorRecep Tayyip Erdogan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-02

View on ClinicalTrials.gov More Impacted Third Molar trials